Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-19T02:26:47.348Z Has data issue: false hasContentIssue false

Chapter 24 - Pharmaceuticals and Alternatives for Wellness

from Part IV - Wellness Interventions

Published online by Cambridge University Press:  18 September 2020

By
Thomas Parisi ,
Blaire Heath ,
Raymond Wen  and
Waguih William IsHak
Edited by
Waguih William IsHak
Waguih William IsHak
Affiliation:
Cedars-Sinai Medical Center and David Geffen School of Medicine, University of California Los Angeles (UCLA)
Get access

Summary

The relationship between mind, body, and spirit has inspired philosophers, artists, physicians, and scientists for centuries. Daring to reach for our dreams yet fearing to lose that which we have fought so hard to attain, the tools developed to navigate the human condition have pushed the limits of technological advancement. Although the landscape and its demands will continue to evolve, a common thread throughout time is humanity’s desire to reach its potential, to function at peak capacity. This guiding light has led to the development of medicine, which has been utilized as a means by which to save the fragile yet resilient corporeal form, as well as an instrument to transcend its bounds. Medicine as an art involves the use of wide-ranging modalities, including pharmaceuticals. Experiencing health in all meanings of the word involves the absence of illness, as well as the optimization of health.

Type
Chapter
Information
The Handbook of Wellness Medicine , pp. 302 - 314
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

World Health Organization. WHOQOL: measuring quality of life. 2019. www.who.int/healthinfo/survey/whoqol-qualityoflife/en (accessed April 7, 2019).Google Scholar
Health Affairs. Spending on prescription drugs in the US: where does all the money go? 2018. www.healthaffairs.org/do/10.1377/hblog20180726.670593/full (accessed April 7, 2019).Google Scholar
Council for Responsible Nutrition Foundation. Economic impact of the dietary supplement industry. 2016. www.crnusa.org/resources/economic-impact-dietary-supplement-industry (accessed April 7, 2019).Google Scholar
World Health Organization. Depression. 2018. www.who.int/news-room/factsheets/detail/depression (accessed April 8, 2019).Google Scholar
IsHak, WW, Bonifay, W, Collison, K, et al. The recovery index: a novel approach to measuring recovery and predicting remission in major depressive disorder. J Affect Disord 2017; 208: 369–374.CrossRefGoogle ScholarPubMed
Cipriani, A, Furukawa, T, Salanti, G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–1366.Google Scholar
Apaydin, EA, Maher, AR, Shanman, R, et al. A systematic review of St. John’s wort for major depressive disorder. Syst Rev 2016; 5: 148.CrossRefGoogle ScholarPubMed
Papakostas, GI, Mischoulon, D, Shyu, I, Alpert, JE, Fava, M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors (SRIs) for SRI- non-responders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatr 2010; 167: 942–948.Google Scholar
Mischoulon, D, Price, LH, Carpenter, LL, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry 2014; 75: 370–376.Google Scholar
Sarris, J, Papakostas, GI, Vitolo, O, Mischoulon, D. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Clin Psychiatr 2014; 75: 855–863.Google Scholar
Bradley, M, McElhiney, M, Rabkin, J. DHEA and cognition in HIV-positive patients with non-major depression. Psychosomatics 2012; 53: 244–249.Google Scholar
Ben Dor, R, Marx, CE, Shampine, LJ, Rubinow, DR, Schmidt, PJ. DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA’s antidepressant action. Psychopharmacology (Berl) 2015; 232: 3375–3383.CrossRefGoogle Scholar
Russo, SJ, Murrough, JW, Han, MH, Charney, DS, Nestler, EJ. Neurobiology of resilience. Nat Neurosci 2012; 15: 1475–1484.Google Scholar
Jacobsen, JP, Krystal, AD, Krishnan, KR, Caron, MG. Adjunctive 5-hydroxytryptophan slow-release for treatment-resistant depression: clinical and preclinical rationale. Trends Pharmacol Sci 2016; 37: 933–944.Google Scholar
Van Hiele, LJ. L-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with “therapy-resistant” depressions. Neuropsychobiology 1980; 6: 230–240.Google Scholar
Turner, EH, Loftis, JM, Blackwell, AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxtryptophan. Pharmacol Ther 2006; 109: 325–328.Google Scholar
Davis, JI, Senghas, A, Brandt, F, Ochsner, KN. The effects of BOTOX injections on emotional experience. Emotion 2010; 10: 433–440.Google Scholar
Finzi, E, Rosenthal, NE. Treatment of depression with obotulinumtoxinA: a randomized, double-blinded, placebo controlled trial. J Psychiatr 2014; 52: 1–6.Google Scholar
Woller, MA, de Boer, C, Kalak, N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr 2012; 45: 574–581.Google Scholar
National Institute of Mental Health. Anxiety disorders. 2018. www.nimh.nih.gov/health/topics/anxiety-disorders/index.shtml (accessed April 25, 2019).Google Scholar
Baldwin, D, Woods, R, Lawson, R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011; 342: d1199.CrossRefGoogle ScholarPubMed
Boerner, RJ, Sommer, H, Berger, W, et al. Kava-kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder: an 8-week randomized, double-blind multi-centre clinical trial in 129 outpatients. Phytomedicine 2003; 10: 38–49.CrossRefGoogle ScholarPubMed
Sarris, J, Stough, C, Teschke, R, et al. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother Res 2013; 27: 1723–1728.Google Scholar
Rowe, A, Zhang, LY, Ramzan, I. Toxicokinetics of kava. Adv Pharmacol Sci 2011; 2011: 326724.Google Scholar
Smith, K, Leiras, C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: a systematic review and analysis of randomized clinical trials. Complement Ther Clin Pract 2018; 33:107–117.Google Scholar
Blessing, EM, Steenkamp, MM, Manzanares, J, Marmar, CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 2015; 12: 825–836.Google Scholar
Shannon, S, Lewis, N, Lee, H, Hughes, S. Cannabidiol in anxiety and sleep: a large case series. Perm J 2019; 23: 18-041.Google Scholar
Jerome, S, Alexander, P, Isaac, S, Con, S, Andrew, S. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. J Eur Coll Neuropsychol 2011; 21: 841–860.Google Scholar
Bent, S, Padula, A, Moore, D, Patterson, M, Mehling, W. Valerian for sleep: a systematic review and meta-analysis. Am J Med 2006; 119: 1005–1012.Google Scholar
Miyasaka, LS, Natallah, ÁN, Soares, B. Valerian for anxiety disorders. Cochrane Database Syst Rev 2006; 4: CD004515.Google Scholar
Siegfried, K, Markus, G, Walter, EM, Hans-Peter, V, et al. Lavender oil preparation silexan is effective in generalized anxiety disorder: a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 2014; 17: 859–869.Google Scholar
Siegfried, K, Walter, EM, Hans-Peter, V, et al. Silexan in anxiety disorders: clinical data and pharmacological background. World J Biol Psychiatry 2018; 19: 412–420.Google Scholar
Wilkinson, SM, Love, SB, Westcombe, AM, et al. Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer: a multicenter randomized controlled trial. J Clin Oncol 2007; 25: 532–539.CrossRefGoogle Scholar
Kennedy, DO, Scholey, AB, Wesnes, KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl) 2000; 4: 416–423.Google Scholar
IsHak, WW, Bagot, K, Thomas, S, et al. Quality of life in patients suffering from insomnia. Innov Clin Neurosci 2012; 9: 13–26.Google ScholarPubMed
Auld, F, Maschauer, EL, Morrison, I, et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev 2017; 34: 10–22.Google Scholar
National Center for Complementary and Integrative Health. NIH analysis shows Americans are in pain. 2015. https://nccih.nih.gov/news/press/08112015 (accessed April 1, 2019).Google Scholar
Katz, N. The impact of pain management on quality of life. J Pain Symptom Manage 2002; 1(Suppl.): S38–S47.Google Scholar
Beaudart, C, Biver, E, Bruyére, O, et al. Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res 2018; 5: 413–418.Google Scholar
World Health Organization. Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level: summary meeting report Brussels, Belgium. 2004. www.who.int/chp/topics/Osteoporosis.pdf (accessed April 2, 2019).Google Scholar
Moskowitz, RW. The burden of osteoarthritis: clinical and quality-of-life issues. Am J Manage Care 2009; 8(Suppl.): S223–S229.Google Scholar
Neogi, T. The epidemiology and impact of pain in osteoarthritis. Osteoarthr Cartil 2013; 9: 1145–1153.CrossRefGoogle Scholar
van Walsem, A, Pandhi, S, Nixon, RM, et al. Relative benefit–risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther 2015; 17: 66.CrossRefGoogle ScholarPubMed
Daily, JW, Yang, M, Park, S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized controlled clinical trials. J Med Food 2016; 8: 717–729.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×